Midatech Pharma plc is a pharmaceutical company focused on the research and development of drug delivery technologies and therapeutic solutions across the United Kingdom, Europe, and international markets. Its active pipeline includes MTX110, an investigational direct-delivery treatment for aggressive brain tumors such as diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. Also in development are MTX114, a topical immunosuppressant for managing psoriasis; MTD211, an extended-release formulation of brexpiprazole for schizophrenia and as an adjunct for major depressive disorder; and MTD219, a long-acting version of tacrolimus designed to mitigate the risk of organ transplant rejection. The company also leverages proprietary drug delivery platforms: Q-Sphera, a polymer microsphere microtechnology for sustained drug release; MidaSolve, an oligosaccharide nanotechnology enabling the solubilization and direct, localized liquid administration of drugs into tumors; and MidaCore, a gold nanoparticle system engineered for targeted delivery of chemotherapeutic or immunotherapeutic agents to disease sites. Founded in 2000, Midatech Pharma plc is headquartered in Cardiff, United Kingdom.


Net sales
Gross margin
Net income